Terms: = Leukemia AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1
362 results:
1. Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with atr Inhibitors.
Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
[TBL] [Abstract] [Full Text] [Related]
2. Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival.
Scaviner J; Bagacean C; Christian B; Renaudineau Y; Mignen O; Abdoul-Azize S
Eur J Pharmacol; 2024 May; 971():176515. PubMed ID: 38547958
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the NTSR2/TrkB oncogenic pathway in chronic lymphocytic leukemia.
Ikhlef L; Yassine M; Chandouri B; Rivière L; Naves T; Dmytruk N; Gachard N; Jauberteau MO; Gallet PF
Sci Rep; 2024 Mar; 14(1):6084. PubMed ID: 38480783
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of Selective and Potent atr Degrader for Exploration its Kinase-Independent Functions in Acute Myeloid leukemia Cells.
Wang Y; Wang R; Zhao Y; Cao S; Li C; Wu Y; Ma L; Liu Y; Yao Y; Jiao Y; Chen Y; Liu S; Zhang K; Wei M; Yang C; Yang G
Angew Chem Int Ed Engl; 2024 Apr; 63(17):e202318568. PubMed ID: 38433368
[TBL] [Abstract] [Full Text] [Related]
5. Indigofera suffruticosa aerial parts extract induce G2/M arrest and atr/CHK1 pathway in Jurkat cells.
Tran HL; Lai KH; Chang HS; Chen YS; Wang HC; Yang SS; Chang HW; Hsu CM; Yen CH; Hsiao HH
BMC Complement Med Ther; 2024 Jan; 24(1):28. PubMed ID: 38195460
[TBL] [Abstract] [Full Text] [Related]
6. Suppression of DNMT1 combined with ATM or atr inhibitor as a therapeutic combination of acute myeloid leukemia.
Liu L; Hu X; Feng J; Lei A; Huang S; Liu X; Liu H; Luo L; Yao W
Anticancer Drugs; 2024 Mar; 35(3):251-262. PubMed ID: 38164802
[TBL] [Abstract] [Full Text] [Related]
7. Risk Factors for Treatment-Related Amenorrhea in Female Survivors of Childhood and Adolescent Cancer: 10-Year Experiences at Oncofertility Clinic in Korean Tertiary Center.
Park SJ; Choi JY; Kang HJ; Lee YJ; Lee YA; Han JY; Kim SW; Kim H; Ku SY
J Adolesc Young Adult Oncol; 2024 Feb; 13(1):162-169. PubMed ID: 38064519
[No Abstract] [Full Text] [Related]
8. R-Loop Accumulation in Spliceosome Mutant leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.
Liu ZS; Sinha S; Bannister M; Song A; Arriaga-Gomez E; McKeeken AJ; Bonner EA; Hanson BK; Sarchi M; Takashima K; Zong D; Corral VM; Nguyen E; Yoo J; Chiraphapphaiboon W; Leibson C; McMahon MC; Rai S; Swisher EM; Sachs Z; Chatla S; Stirewalt DL; Deeg HJ; Skorski T; Papapetrou EP; Walter MJ; Graubert TA; Doulatov S; Lee SC; Nguyen HD
Cancer Res; 2024 Feb; 84(4):577-597. PubMed ID: 37967363
[TBL] [Abstract] [Full Text] [Related]
9. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract] [Full Text] [Related]
10. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, atr or WEE1.
Pfeiffer C; Grandits AM; Asnagli H; Schneller A; Huber J; Zojer N; Schreder M; Parker AE; Bolomsky A; Beer PA; Ludwig H
Leukemia; 2024 Jan; 38(1):181-192. PubMed ID: 37898670
[TBL] [Abstract] [Full Text] [Related]
11. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies.
Luo Y; Qie Y; Gadd ME; Manna A; Rivera-Valentin R; To T; Li S; Yassine F; Murthy HS; Dronca R; Kharfan-Dabaja MA; Qin H
Cancer Immunol Immunother; 2023 Dec; 72(12):4031-4047. PubMed ID: 37814001
[TBL] [Abstract] [Full Text] [Related]
12. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
14. T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia.
Montironi C; Jacobs CF; Cretenet G; Peters FS; Schomakers BV; van Weeghel M; Kater AP; Simon-Molas H; Eldering E
Blood Adv; 2023 Nov; 7(21):6540-6552. PubMed ID: 37552122
[TBL] [Abstract] [Full Text] [Related]
15. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML.
Bamezai S; Pulikkottil AJ; Yadav T; Vegi NM; Mueller J; Mark J; Mandal T; Feder K; Ihme S; Song C; Rosler R; Wiese S; Hoell JI; Kloetgen A; Karsan A; Kumari A; Wojenski L; Sinha AU; Gonzalez-Menendez I; Quintanilla-Martinez L; Donato E; Trumpp A; Kruse E; Hamperl S; Zou L; Rawat VPS; Buske C
Blood; 2023 Jul; 142(1):90-105. PubMed ID: 37146239
[TBL] [Abstract] [Full Text] [Related]
16. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Thompson PA; Keating MJ; Ferrajoli A; Jain N; Peterson CB; Garg N; Wang SA; Jorgensen JL; Kadia TM; Bose P; Pemmaraju N; Short NJ; Wierda WG
Leukemia; 2023 Jul; 37(7):1444-1453. PubMed ID: 37138019
[TBL] [Abstract] [Full Text] [Related]
17. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells.
Li L; Hu X; Nkwocha J; Sharma K; Kmieciak M; Mann H; Zhou L; Grant S
Cell Oncol (Dordr); 2023 Oct; 46(5):1369-1380. PubMed ID: 37126127
[TBL] [Abstract] [Full Text] [Related]
18. Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse.
Sato S; Zhang XK; Matsuoka N; Sumichika Y; Saito K; Yoshida S; Matsumoto H; Temmoku J; Fujita Y; Asano T; Migita K
Lupus Sci Med; 2023 Apr; 10(1):. PubMed ID: 37094946
[TBL] [Abstract] [Full Text] [Related]
19. ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias.
Golovine K; Abalakov G; Lian Z; Chatla S; Karami A; Chitrala KN; Madzo J; Nieborowska-Skorska M; Huang J; Skorski T
Blood Cancer J; 2023 Mar; 13(1):42. PubMed ID: 36959186
[TBL] [Abstract] [Full Text] [Related]
20. Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib.
Tang J; Zhong J; Yang Z; Su Q; Mo W
Biochem Biophys Res Commun; 2023 Apr; 650():96-102. PubMed ID: 36774689
[TBL] [Abstract] [Full Text] [Related]
[Next]
